The BioHub: The Top Voices in Biotech

In this episode of The BioHub Podcast, Max sits down with Jonathan Sadeh, EVP, Head of R&D and Chief Medical Officer at Bausch Health.Jonathan is a physician-scientist with more than 20 years of experience across global pharma, having held senior leadership roles at Bristol Myers Squibb, Sanofi, AstraZeneca, and Schering-Plough.In this conversation, we discuss his journey through big pharma, the evolution of drug development and R&D, what it takes to progress inside large organisations, and why he chose to join Bausch at this stage of his career.We also explore how the industry is changing, how companies are adapting, and what leadership looks like in today’s biotech and pharma landscape.

In this episode of The BioHub Podcast, Ben is joined by Craig Thompson, CEO of Cerevance.Craig has spent over three decades across biotech and pharma, leading companies through major stages of growth, development and strategic transformation. Today, he leads Cerevance, a clinical-stage neuroscience company focused on developing new medicines for neurological and neuropsychiatric diseases.In this conversation, Ben and Craig discuss Cerevance’s work in Parkinson’s disease, the challenges of late-stage CNS development, what it takes to build conviction in neurodegeneration, and how companies think about execution, leadership and potential commercialization in one of the most complex areas of medicine.They also explore Craig’s journey through the industry, the lessons he has carried across leadership roles, and why patient impact remains central to building a successful biotech company.

In this episode of The BioHub Podcast, Max sits down with Amin Zargar, CEO of ResVita Bio, and Chad Miller, the company’s Chief Technology Officer.ResVita is developing a new class of treatments for skin diseases using engineered bacteria to deliver continuous protein therapy directly on the skin — an approach designed to transform how chronic dermatological conditions are treated.Amin brings deep expertise in synthetic biology from Jay Keasling’s lab at UC Berkeley, while Chad’s background spans protein design research in David Baker’s lab and founding Nosis Bio.In this conversation, we talk about how ResVita was founded, the science behind continuous protein therapy, why Chad joined the mission, and what’s next as the company moves toward the clinic.

Today, we’re joined by two leaders at nChroma Bio, a company working to redefine the future of genetic medicine through epigenetic engineering and next-generation targeted delivery technologies.Melissa Bonner, Chief Scientific Officer, and Dr. Jenny Marlowe, Chief Development Officer, are helping lead the development of therapies designed not just to edit genes, but to control how genes are turned on and off — without permanently changing the underlying DNA sequence.nChroma is combining programmable epigenetic editors with advanced delivery systems like lipid nanoparticles and engineered virus-like particles to create highly targeted therapies for diseases affecting the liver, cardiovascular system, blood, and central nervous system. Their lead program, CRMA-1001, is being developed as a potential functional cure for chronic hepatitis B and hepatitis D. What makes this especially exciting is that nChroma’s approach aims to regulate gene expression in a durable and potentially safer way than traditional gene editing approaches that cut DNA.

In this episode we welcome Tom Frohlich the CEO of Jade Biosciences

Today’s guest is James Mackay, Chief Executive Officer of Crystalys — a biotech company tackling one of the most common yet often overlooked metabolic diseases: gout.James brings decades of experience across the biotechnology and pharmaceutical industries, including senior leadership roles and a track record of helping bring innovative therapies to market. His career spans global pharma and emerging biotech, where he’s built a reputation for translating cutting-edge science into real-world treatments.At Crystalys, James is leading the development of novel therapies designed to address gout at its root — targeting the underlying biology of uric acid crystal formation and inflammation, with the goal of delivering more effective, long-lasting solutions for patients.The company is also gaining strong momentum, having recently raised a Series A round to accelerate its research and clinical development efforts.In today’s conversation, we’ll explore James’s journey, the science behind Crystalys’ approach to gout, and what this latest funding milestone means for the future of the company.

In this episode ofThe BioHub Podcast by Avetix, Ben sits down with Shawn Singh, CEO of Vistagen Therapeutics, to discuss his career across biotech, venture capital, CROs, public markets, and the evolution of neuropsychiatry drug development.With more than 30 years of experience spanning private and public biotechnology, medtech, pharma, venture capital, and contract research, Shawn brings a uniquely broad perspective on what it takes to build and lead companies through different stages of growth.In this conversation, Shawn shares reflections on the lessons learned from building and financing life sciences companies, leading through changing market cycles, and staying focused on long-term value creation in CNS. He also discusses Vistagen’s approach to developing differentiated treatments for anxiety, depression, and other neuropsychiatric disorders, the importance of patient need in shaping strategy, and what it takes to advance innovation in an area where new treatment options are urgently needed.

In this episode of The BioHub Podcast, we’re joined by Karen Lewis, Chief People Officer at Cardurion Pharmaceuticals, to discuss her career journey through biotech, talent acquisition, HR leadership, public and private companies, and the realities of building culture in fast-growing organisations.Karen shares how her career began at the bench as a scientist before moving into recruitment, HR business partnering, and senior people leadership roles across some of the most recognised names in the life sciences industry.We explore what it really takes to scale biotech companies, how culture changes as businesses grow, the difference between big pharma and smaller biotech environments, and why leadership support, transparency and care matter so much during moments of change.

On this episode we discuss the AAVantgarde story with CEO, Natalia Misciatelli. Founded by Professor Alberto Auricchio in 2021 as a spin-out from Telethon Institute of Genetics and Medicine in Naples, we discuss their dual-vector and intein-based platforms and how the team are positioning to deliver large therapeutic genes for inherited retinal diseases. Backed by household VC names including; Forbion, Atlas Venture, & Sofinnova, Natalia and the team are pursuing game-changing prospects for Stargardt & Usher1b patients.Check this episode out to hear more about their programs, particularly ahead of ARVO where the team will share data from their LUCE ph1/2 study in Usher1b.

We were delighted to welcome Ken Macnamara, an accomplished biotech executive with deep experience spanning product development, advanced therapeutics, and company leadership, onto The BioHub! Over the course of his career, Ken has held senior roles across innovative life sciences businesses, helping translate cutting-edge science into real-world therapies and scalable commercial platforms. He currently serves as CEO of Trogenix, where he is focused on advancing next-generation precision genetic medicines. With a background that bridges science, operations, and strategy, Ken brings a rare perspective on what it takes to build successful biotech companies in an increasingly complex healthcare landscape

In this episode of The BioHub Podcast by Avetix, Ben sits down with Dr. Arun Swaminathan, CEO of Coya Therapeutics, a clinical-stage biotechnology company developing therapies designed to enhance regulatory T cell function and target systemic inflammation and neuroinflammation.Arun brings more than 20 years of healthcare leadership experience across corporate strategy, business development, operations, and deal-making. At Coya, he is helping lead the company’s work in severe neurodegenerative diseases, including ALS, Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease, with a focus on immunomodulatory and Treg-based therapeutic approaches. In this conversation, we discuss the evolving treatment landscape in neurodegeneration, the role of neuroinflammation in CNS drug development, what it takes to build and finance a clinical-stage biotech, and how combination therapeutic strategies could shape the next generation of disease-modifying treatments.

In this episode of The BioHub Podcast, Max sits down with Haseeb Ahmad, CEO of Purespring Therapeutics.Haseeb brings over 25 years of experience in the life sciences industry, including leadership roles at Novartis where he oversaw a $15B business across Europe and led their gene therapies division.But this conversation goes beyond titles.Haseeb shares how his upbringing in Liverpool and the influence of his parents shaped his mindset, leadership style, and approach to building companies.We also discuss his transition from big pharma to biotech, what makes Purespring so exciting, and why targeting kidney disease through gene therapy could be transformative for patients.

Today, we’re joined by a leader working at the cutting edgeof immunology and eye disease. Elizabeth Jeffords is the CEO of Iolyx Therapeutics, a clinical-stage biotech company focused on transforming how we treat inflammatory and autoimmune diseases of the eye.Iolyx sits at the emerging intersection of immunology andophthalmology—what’s often called immuno-ophthalmology. The company is developing targeted therapies designed to treat ocular inflammation right at its source, with the goal of replacing older treatments like steroids and broadimmunosuppressants with more precise, better-tolerated options. Their lead program is a topical immunomodulatory therapy forautoimmune dry eye disease, which has already shown promising results in Phase 2 clinical trials—demonstrating meaningful improvements in ocular surface health for patients with underlying inflammatory conditions. In today’s conversation, we’ll explore how her career led her into biotech leadership, why the eye is such a unique and challenging organ for drug development, the Biotech CEO sisterhood and how immunology could reshape the future of treating chronic eye disease.

Welcome to today’s episode, where we sit down with Derek Adams, CEO of Stellular Bio. Derek has been helping steer Stellular Bio at the intersection of advanced biomanufacturing and next-generation therapeutic development—turning complex scientific challenges into real-world medical possibilities.Prior to Stellular, Derek was Chief Manufacturing and Technology Officer at bluebird bio, one of the most well-known pioneers in gene therapy and advanced biologics, and had prior roles at Evelo Biosciences, Epiva Biosciences, Alexion Pharmaceuticals.

In this episode of The BioHub Podcast, Max sits down with Harold Bernstein.Harold brings decades of experience across biotech and pharma, with a career spanning leadership roles, company building, and advancing innovative therapies through development.In this conversation, we explore Harold’s journey through the industry, the lessons he’s learned along the way, and his perspective on how biotech companies can successfully navigate today’s evolving landscape.We also discuss the science behind what he’s working on today, the challenges of building in biotech, and where the industry is heading next.

In this episode of the BioHub Podcast, Amber is joined by Daniel, Co-Founder and CEO of Model Medicines.Model Medicines is building an AI-driven drug discovery platform with a fundamentally different approach, focusing on applying machine learning to problems where traditional methods have failed.Daniel shares how the team is targeting biological “choke points” across multiple diseases, why throughput and inference may matter more than model size, and how they’re thinking about scaling into development as programmes move towards the clinic.

We sit down with Rafiq Hasan, co-founder & CEO of Complement Therapeutics, at their London offices to unpack a milestone-loaded past 6 months. Rafiq shares the company's thesis, based on research from Manchester university, and how in practice they are targeting the complement system. We also dig into a landmark moment for the company - the recent dosing of patients in OPTI-GAIN, their Phase 1/2 clinical trial targeting Geographic Atrophy, a leading cause of irreversible vision loss. Another topic of discussion centers around what it's took to build a biotech from the ground up over the past few challenging years.Definitely worth a listen for anyone building in ophthalmology, gene therapy, or across UK biotech.

In this episode of The BioHub Podcast, Max sits down with Lu Han, CEO of Imviva Biotech.Lu’s journey spans science, venture investing, and now company building, bringing a unique perspective to one of the most competitive areas in biotech.Imviva is focused on developing off-the-shelf CAR-T therapies, aiming to make cell therapies more scalable and accessible for patients across oncology and autoimmune diseases.In this conversation, we talk about Lu’s path from scientist to CEO, the global dynamics shaping biotech, and how the next wave of cell therapy is evolving.

Today's guest is Dee Dragon, she sits at the interface of People Strategy at Senti Bio. She has entered the industry in the last 6+ years and has really made a difference in the culture at Senti. Not only that, she has co-founded the Biotech CHRO Sisterhood, a movement that is taking the biotech industry by storm. In this episode we explore Dee's journey and how she entered the biotech space, and why her passion in what she does has had a ripple effect through the industry.

Today’s guest sits at the intersection of cutting-edge science and bold entrepreneurship. Dr. Lan Huang is the Co-Founder, CEO, and Chairman of SEED Therapeutics, where she’s leading the charge in developing next-generation medicines through targeted protein degradation—an approach that’s redefining what’s possible in drug discovery.But she didn’t stop at the lab bench. Lan is also a seasoned biotech entrepreneur, having founded multiple companies across the U.S. and China, including BeyondSpring, which she led to a successful public listing. Across more than 15 years in the industry, she’s built a reputation for translating complex science into real-world treatments.In this episode, we explore her journey from researcher to CEO, the promise of molecular glue therapies, and what it takes to build a biotech company at the frontier of innovation.

In this episode of The BioHub Podcast, Amber sits down with Nazli Azimi, Co-founder and CEO of Therna Biosciences.Nazli has previously founded and scaled two biotech companies through to acquisition, and is now focused on building AI-driven platforms to design programmable RNA medicines.In this conversation, we explore why many first-generation AI drug discovery companies struggled, and why grounding models in real biological questions and high-quality data is critical.We also discuss what it means to “program” RNA medicines, from designing molecules with specific properties to controlling gene expression at the transcript level.Nazli shares a real-world example of designing an RNA molecule for a pulmonary fibrosis patient in a matter of days, and what this could mean for the future of personalised therapies.Where AI in drug discovery starts to move beyond hype and into reality.

On this episode we meet Sam Possemiers, CEO at MRM Health, the leading developers of microbiome-based therapeutics within IBD. We discuss the origins of their CORAL platform, which was brought to life in the basement of Ghent University by Willy Verstraete. The concept of "Microbial Resource Management" and how Sam used the profits from his successful CRO, ProDigest, to self-fund the seed and go all-in on MRM. Sam & the team's latest milestones include ph2b STARFISH-UC trial initiation, & an upcoming study in Pouchitis. We also close on what it took to raise their €55million Series B, which Sam closed whilst literally halfway up an Alp, and the learnings Sam has taken from that process.

In this episode of The BioHub Podcast, Max sits down with Dr. Atta Behfar, Co-Founder of Rion and Professor of Regenerative Medicine at Mayo Clinic.Atta’s work at Mayo led to a key discovery that became the foundation for Rion, a clinical-stage company developing exosome-based therapeutics through its Purified Exosome Product (PEP) platform.In this conversation, Atta shares the story behind that discovery, how it translated into a company, and the potential of cell-free regenerative medicine to make advanced biologics more accessible to patients.We also discuss Rion’s progress in wound healing, how the team has been built, and what’s next for their pipeline.A fascinating look at how breakthrough science becomes real therapies.

In this episode of The BioHub Podcast, Max sits down with Srinivas Rao, CEO of atai Beckley.Srini has been there from the very beginning, helping build atai into one of the leading companies in the mental health and psychedelics space, and now leading the next chapter following the merger with Beckley.In this conversation, we talk about how atai was founded, the evolution of the psychedelics space, and what it takes to build in one of the most challenging and closely watched areas in biotech.We also discuss Srini’s transition into the CEO role, the strategy behind the merger, and what’s coming next for the company.

We were delighted to welcome Daniel Fero, Managing Director of OMX Ventures, onto the Biohub. He's working at the intersection of science, startups, and investment — where breakthrough research meets real-world impact.Daniel Fero is a venture investor focused on biotech and life sciences, with experience spanning early-stage company building and healthcare innovation. Based in the Greater Boston area — one of the world’s leading hubs for biomedical research — Daniel works closely with scientists and founders to help translate cutting-edge discoveries into companies that can reshape how we understand and treat disease.He’s particularly engaged in the world of biotech venture capital, where deep scientific insight meets high-stakes decision-making about which ideas are worth backing, scaling, and bringing to market. His work touches everything from university spinouts to emerging therapeutics, reflecting a broader mission: accelerating the path from lab bench to patient impact.In this conversation, we’ll explore Daniel’s journey into venture investing, what he looks for in early-stage biotech companies, and how innovation is evolving at the frontier of healthcare and life sciences.

In todays episode we talk about Dan's career and the work Pelage are doing, leading innovation in the hair loss space.

In this episode of The BioHub Podcast, Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma.Jeremy’s career spans roles at Genentech, Opsona, and Inflazome, which was acquired by Roche before stepping into the CEO role at Poolbeg, a public biotech taking a different approach to drug development.In this conversation, we talk about how Poolbeg is building a more capital-efficient, data-driven model, the realities of today’s biotech market, and how companies can position themselves to succeed in a tougher funding environment.It’s a great in-person discussion on what it really takes to build differently in biotech today.

We recently spoke to Lance Baldo, CEO of Beacon Therapeutics, during the Jefferies Healthcare Conference. Beacon's Vista ph3 trial for laru-zova, their AAV Gene Therapy for X-Linked Retinitis Pigmentosa, has completed enrolment with topline expected in mid-2026.Listen in to hear about Lance's career, from roles with Roche in both Switzerland & New Zealand to a return to the US with Genentech's ophthalmology division, and how he's drawn on those experiences in his role as CEO of Beacon.We also cover Lance's experience as a first-time CEO, and his advice for other executives making that transition, on topics as broad as fundraising, regulatory discussions, and team building. And of course, we cover the story behind Beacon & their mission to deliver a step-change for XLRP patients globally. 

Today’s guest is Ashley Zehnder, the co-founder and CEO of Fauna Bio—a pioneering biotech company unlocking insights from the natural world to transform human health.With a background in genomics and a passion for translating cutting-edge science into real-world therapies, Ashley is leading a new frontier in drug discovery—one that looks to nature’s own evolutionary experiments to uncover novel treatments for disease.Under her leadership, Fauna Bio is redefining how we approach medicine by combining comparative biology, machine learning, and massive genomic datasets to identify breakthroughs that traditional methods might miss.In this episode, we’ll explore Ashley’s journey from scientist to CEO, the bold vision behind Fauna Bio, and how studying the biology of extraordinary animals could reshape the future of healthcare.

In this episode of The BioHub Podcast, Max sits down with Robert Jacks, President and CEO of Sparrow Pharmaceuticals.Robert brings more than 25 years of experience in biotech, having founded or co-founded multiple companies and raised over $300 million across his career. From roles in corporate development at Pfizer to leading companies through development, approval, and exit, he’s seen the industry from every angle.In this conversation, Robert shares his journey into biotech leadership, the story behind Sparrow, and what it takes to build and scale companies while staying lean and focused.They also discuss raising capital in today’s market, navigating the challenges of biotech, and where the industry is heading next.

In this episode, we’re joined by Jenny Yang, Founder and CEO of Outpost Bio, a company building an AI-driven platform to understand how the human microbiome interacts with drugs, food, and other interventions.Jenny shares her journey from machine learning and genomics research through to her PhD at the University of Oxford and experience at Exscientia, before founding Outpost Bio.We discuss why the microbiome remains an underexplored layer in drug discovery, how advances in AI are enabling more complex biological modelling, and the role of high-quality data in building systems that can translate into real-world impact.

In this episode of The BioHub Podcast, Max sits down with Cary Claiborne, CEO of Adial Pharmaceuticals.Cary’s career spans finance, M&A, and leadership across multiple public biotech companies before stepping into the CEO role at Adial. The company is focused on developing genetically targeted therapies for addiction, starting with alcohol use disorder.In this conversation, Cary shares his transition into biotech leadership, what it’s like running a micro-cap clinical-stage company, and how Adial is approaching one of the most complex and underserved areas in medicine.They also discuss leadership, resilience, and the realities of building and financing biotech companies in today’s market.

Today’s guest brings one of the broadest and most thoughtful perspectives in neuroscience, spanning clinical practice, drug development, investing, and company building.Dr. Spyros Papapetropoulos is a neurologist, neuroscientist, and biotech leader who has spent his career at the intersection of science, medicine, and innovation. With deep experience across both large pharma and emerging biotech, he has built a reputation for translating complex neuroscience into clear strategic direction - helping shape how new therapies move from idea to impact.Over the years, Spyros has worked across multiple dimensions of the CNS ecosystem, from research and development through to leadership, investing, and advising. His work has given him a unique vantage point on what it really takes to build successful neuroscience companies, where the field is heading, and why progress in CNS demands a different kind of thinking.He is also the author of Mind Odyssey, a book that reflects on neuroscience, innovation, and the future of brain health - themes that closely mirror the work he continues to do across the biotech landscape today.In this conversation, we explore Spyros’ journey through neuroscience, his view on the current state of the CNS biotech ecosystem, where drug development is heading next, and what it takes to build companies, teams, and ideas that can genuinely move the field forward.

Today’s guest brings a rare blend of medicine, science, and strategy to the frontlines of biotech innovation.Dr. Megan McGill is a physician-scientist and biotech leader with over two decades of experience spanning clinical medicine, neuroscience research, and drug development. Trained as both an MD and PhD, her work has focused deeply on understanding the brain—particularly the mechanisms behind neurodegenerative diseases like Parkinson’s.But Megan didn’t stop at the lab or the clinic. She’s also worked at the highest levels of strategy consulting with McKinsey & Company, and held leadership roles at cutting-edge biotech firms like Regenxbio and BridgeBio, helping translate scientific breakthroughs into real therapies for patients.Today, she serves as CEO of Brenig Therapeutics, where she’s leading efforts to develop next-generation, AI-enabled treatments targeting the underlying biology of neurological disease.In this conversation, we’ll explore her journey from medicine to biotech leadership, the future of drug development, women in leadership positions and what it takes to turn scientific insight into life-changing innovation.

In this episode of The Biohub Podcast, Amber sits down with Tess Bevers CEO and Founder of Novogaia, a company combining AI and mass spectrometry to discover new drug molecules from fungi.We explore why fungi remain one of the most underexplored sources of chemistry in nature, the historical bottlenecks in natural product drug discovery, and how new advances in AI are helping researchers prioritise which molecules could actually become viable drugs.Tess also shares how Novogaia is building its discovery platform, why focus matters in biotech, and what’s driving the company’s move from London to San Francisco.

Welcome to another episode of The BioHub.Today I’m joined by Jason Tardio —COO of Immunic Therapeutics, a clinical stage biotech for oral small molecule therapies for chronic inflammatory and autoimmune diseases. In this episode we explore Jason's awesome background, from starting as a sales rep and climbing the ladder into his position today, as COO.

Welcome to another episode of The BioHub.Today I’m joined by Steffen-Sebastian Bolz — scientist, physician, entrepreneur, and Co-Founder of Aphaia Pharma, a clinical-stage biotech developing precision-targeted drug formulations to treat and prevent metabolic disorders like obesity and prediabetes.We’ll be talking about the science behind Aphaia, why they’re not building with an exit in mind, and how staying lean and under the radar has helped them advance to Phase 2.

In this episode of The BioHub Podcast, Max sits down with Dr. Philippe Chambon, CEO and Co-Founder of EG 427.After more than 30 years in pharma and venture capital — raising over $1 billion to back life science companies — Philippe has made the move from investor to operator, now leading EG 427.The company is pioneering a new approach to neurological disease with pinpoint DNA medicine, designed for precise and durable delivery.In this conversation, Philippe shares his journey into the CEO seat, the inspiration behind EG 427, and why he believes Europe — and France in particular — are entering a new era for biotech innovation.

Today’s guest is Dr. Yerem Yeghiazarians — a leading interventional cardiologist, professor of medicine at the University of California, San Francisco, and a physician-scientist working at the cutting edge of cardiovascular innovation.With medical training from Johns Hopkins and advanced cardiology specialization at Brigham and Women’s Hospital, Dr. Yeghiazarians has spent over two decades at UCSF treating complex heart disease and advancing the field of interventional cardiology.Dr. Yeghiazarians is the co-founder of Soley Therapeutics, a biotech company focused on using AI to better understand how cells respond to stress, injury, and disease — with the goal of transforming how new drugs are discovered and developed.Alongside this, he directs translational research exploring how stem cell therapies can repair heart damage after heart attacks, bridging fundamental science with real-world clinical impact.From the cath lab to the biotech startup world, his career sits at the intersection of medicine, technology, and entrepreneurship — and today, we’ll explore that journey, the future of drug discovery, and what it takes to turn scientific insight into meaningful breakthroughs.

In this episode of The BioHub Podcast, Max sits down with Amit Etkin, Founder and CEO of Alto Neuroscience.Psychiatry is one of the few areas in medicine still dominated by trial and error.Amit is trying to change that.A trained psychiatrist and neuroscientist, Amit founded Alto to bring precision medicine into mental health — using biomarkers to better match patients with the treatments that actually work for them.In this conversation, we get into why CNS drug development has historically struggled, what’s broken in the current system, and how a more data-driven approach could reshape the future of psychiatry.We also talk about Amit’s journey from academia to founder, the realities of building in a tough market, and why now might finally be the turning point for neuroscience.A thoughtful, honest conversation tackling one of the hardest problems in medicine. 🧠

We were delighted to be joined by James Kim (Chief Corporate Officer) and Ronald Li (Chief Executive Officer), at Medera Biopharmaceuticals.Medera is a company at the forefront of pharmaceutical innovation, focused on advancing next-generation therapies and building a globally competitive platform across research, development, and commercialization. As the industry continues to evolve — driven by scientific breakthroughs, regulatory complexity, and shifting market dynamics — Medera is positioning itself to play a meaningful role in shaping what comes next.James and Ronald sit right at the center of that journey. Between them, they bring deep experience across strategy, operations, and scaling healthcare businesses, with a strong focus on translating innovation into real-world impact.

On this episode we welcome Cellares' co-founder, Fabian Gerlinghaus, to discuss their revolutionary, fully automated, cell therapy manufacturing platform.Cell therapies work - the science is proven. Fabian & the team's mission is to deliver these life-changing therapies at scale, to change more patient's lives.On this episode we talk through Fabian's background in robotics, his move to California and the life sciences, and how he and co-founder Omar Kurdi started the Cellares story. Looking ahead, we dig into the technology and, latest milestones (including recently starting GMP manufacturing), whilst also talking through plans for international expansion, and the impressive Series D funding that journey.

Today, we’re joined by Dipal Doshi, a leader at theforefront of modern biotechnology and rare disease innovation. As CEO of Entrada Therapeutics, Dipal has helped build the company from its earliest days into a clinical-stage pioneer focused on unlocking intracellular therapies.With a career that spans investment banking at MerrillLynch, global pharma at Eli Lilly and Company, and senior leadership roles at Amicus Therapeutics, Dipal brings a unique blend of financial, strategic, and commercial expertise to the biotech world.Now Dipal's leading Entrada Therapeutics, who are aclinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, they are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others.

In this episode of The BioHub Podcast, Max sits down with Barry Quart, CEO of Connect Biopharma and one of the most experienced biotech leaders in the industry.Barry’s career spans more than three decades across biotech and pharma, including founding Ardea Biosciences (acquired by AstraZeneca) and leading Heron Therapeutics, where he helped bring multiple drugs through development and approval. Across his career he has played a role in nine FDA-approved medicines.In this conversation, Barry shares the lessons he’s learned building biotech companies, what it really takes to develop successful drugs, and how he thinks about leadership in an industry defined by risk and long timelines.They also dive into Connect Biopharma, the company’s strategy in inflammatory diseases, and the potential of their lead program targeting the IL-4 pathway in asthma and other respiratory conditions.It’s a conversation about building companies, developing medicines, and navigating the realities of biotech.

Today’s guest is Robert Clarke, the CEO of Kinaset — acompany at the forefront of next-generation therapeutics and biotechnology innovation.Robert brings a unique blend of scientific curiosity, strategic leadership, and entrepreneurial drive to the biotech world. With a background spanning life sciences, investment, and company building, he has spent much of his career working at the intersection of science and commercialization — helping translate breakthrough research into real-world medical solutions.At Kinaset, Robert leads the company’s mission to developinnovative therapies aimed at improving outcomes for patients with serious diseases. Under his leadership, the company has been advancing novel approaches in drug discovery and development, building partnerships across the biotech ecosystem, and positioning Kinaset as an emerging player in the global life sciences landscape.

The biggest bottleneck in drug development is no longer discovery, it's in the clinic. Formation Bio's proprietary AI-native platform is changing drug development to bring new treatments to patients faster and more efficiently.We catch up with Emily Gransky, who is shaping the talent strategy behind one of biotechs most exciting stories.Emily previously shaped Flagship & RA Ventures TA strategies, and played a key role in scaling Bluebird Bio from 300 to 800 headcount.During this episode, we discuss how the team are leveraging AI to drive efficiency and quality throughout the recruitment process. We also get Emily's take on the rapid evolution of AI and it's impact on biotech talent.

Ann is the Founder and CEO of Rejuvenate Biomed, a clinical-stage biotechnology company developing combination therapies aimed at targeting the biological mechanisms behind age-related diseases. With more than two decades of experience in pharmaceutical research and development, she has built a career focused on translating cutting-edge science into therapies that can improve patients’ lives.Before launching Rejuvenate Biomed in 2017, Ann held leadership roles at Janssen Pharmaceuticals, part of Johnson & Johnson, where she worked across drug discovery, development, and innovation strategy. Her work has spanned multiple therapeutic areas including oncology, neurology, immunology, and infectious diseases.Ann earned her PhD in neuro-oncology from the University of Zurich and conducted postdoctoral research at ETH Zurich, building a strong scientific foundation that she later brought into the biotech industry.

In this episode of The BioHub, I’m joined by Catherine Isted, Chief Financial Officer of Santhera Pharmaceuticals.Catherine’s career journey is a unique one, from starting as a bench scientist, to nearly two decades in healthcare investment banking, and now leading finance at multiple biotech companies.In this International Women’s Day special, we talk about her path through the industry, the importance of diversity of thought in biotech, her experiences building a career in leadership, and her advice for young women looking to enter the field.

Today I’m joined by Rich Daly, CEO of Catalyst Pharmaceuticals — one of the standout rare-disease success stories in the industry and recently named one of America’s most successful small-cap companies by Forbes.Rich has spent more than 25 years leading organisations across biotech and pharma — including AstraZeneca, BeyondSpring, CARsgen, and others — and now he’s steering Catalyst as they expand their portfolio, grow their footprint, and continue delivering life-changing treatments for patients with rare neuromuscular and neurological diseases.We talk about what drew him to Catalyst, how the company thinks about growth, patient service, and rare-disease strategy, how they find the right drugs in a competitive market, and how Catalyst continues to outperform despite the volatility across biotech.Let’s get into it.

We were delighted to welcome Jason Ehrlich, Co-Founder and CEO of Ollin Biosciences onto the BioHub. Ollin are a clinical-stage biotechnology company focused on advancing next-generation therapies form serious eye diseases, including wet age-related macular degeneration anddiabetic macular edema. Before launching Ollin, Jason served as Chief MedicalOfficer and Chief Development Officer at Kodiak Sciences, where he led clinical development in retinal disease. Earlier in his career, he held senior leadership roles at Genentech, one of the pioneers in biologic medicines, helping advance therapies that have transformed care for patients with vision-threatening conditions.Trained as both a physician and a scientist, Jason brings arare blend of clinical insight, translational research expertise, and strategic leadership. His career sits at the intersection of medicine, innovation, and company building — with a clear focus: delivering meaningful, durable therapies to patients who risk losing their sight.